The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.
Nizar M. Tannir
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Novartis; Onyx; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Eric Jonasch
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Emre Altinmakas
No relevant relationships to disclose
Chaan S. Ng
No relevant relationships to disclose
Wei Qiao
No relevant relationships to disclose
Pheroze Tamboli
No relevant relationships to disclose
Priya Rao
No relevant relationships to disclose
David F. McDermott
Consultant or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Pfizer; Roche
Research Funding - Prometheus
Christopher G. Wood
Research Funding - Pfizer
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer